IP Library Granted Patent US 11,208,630
Granted Patent B2
US 11,208,630 · App. 16/065,546 · Granted Dec 28, 2021

AAV production using suspension adapted cells

Inventors: Nathalie Clement (Gainesville, FL); Barry John Byrne (Gainesville, FL); Laura A. Small (Gainesville, FL)
Assignee: University of Florida Research Foundation, Incorporated
C12N7/00C12N15/86C12N2710/16644C12N2750/14151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,208,630
App. No.
16/065,546
Granted
Dec 28, 2021
Kind
B2
Abstract

Provided herein are methods of improving rAAV production in cells, the method comprising increasing the salt concentration in the media in which the cells are infected or transfected, cultured, or in which they produce AAV. Aspects of the disclosure relate to improved methods of rAAV production by co-infecting suspension adapted cells (e.g., suspension adapted HEK293 cells) with viruses that encode one or more AAV components for producing rAAV particles within the suspension adapted cells.

Claims (14)

1. A method of producing recombinant AAV (rAAV) in suspension-adapted cells comprised in a medium, the method comprising supplementing the medium with between 5 mM and 200 mM sodium chloride (NaCl) prior to or at the same time as co-infecting the suspension-adapted cells with: a first recombinant herpes simplex virus (rHSV) encoding a gene of interest flanked by AAV inverted terminal repeats (ITRs), and a second rHSV encoding AAV rep and cap genes.

2. The method of claim 1 , further comprising diluting or changing the medium after co-infection such that the concentration of NaCl is decreased.

3. The method of claim 2 , wherein the diluting or changing the medium occurs 0.5-8 h after co-infection.

4. The method of claim 1 , wherein the concentration of supplemented NaCl is between 30 mM and 150 mM.

5. The method of claim 1 , wherein the concentration of NaCl is supplemented such that the total concentration of NaCl is between 130 mM and 200 mM.

6. The method of claim 1 , wherein the cells are mammalian or insect cells.

7. The method of claim 1 , wherein the cells containing the produced rAAV are harvested prior to cell lysis.

8. The method of claim 7 , wherein the step of harvesting the cells is performed by centrifugation.

9. The method of claim 1 , wherein the AAV ITRs are AAV-2 ITRs.

10. The method of claim 1 , wherein the suspension-adapted cells are suspension-adapted HEK293 cells.

11. The method of claim 10 , wherein the suspension-adapted HEK293 cells are derived from adherent HEK293 cells.

12. The method of claim 1 , further comprising isolating rAAV from the co-infected suspension-adapted cells.

13. The method of claim 4 , wherein the concentration of supplemented NaCl is between 60 mM to 90 mM.

14. The method of claim 5 , wherein the concentration of NaCl is supplemented such that the total concentration of NaCl is between 135 mM to 180 mM.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 8, 2022
From: UNIVERSITY OF FLORIDA
To: UNITED STATES GOVERNMENT
Reel/Frame 059657/0199 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2018
From: CLEMENT, NATHALIE; BYRNE, BARRY JOHN; SMALL, LAURA A.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 046755/0888 →
Continuity (3)
Provisional Application 62387553 · Dec 24, 2015
Provisional Application 62432204 · Dec 9, 2016
Related Publication 20200224173A1 · Jul 16, 2020
Cited By (1)
US 12,497,257